CN111956608A - 一类具有抗急性淋巴细胞白血病活性的npm结合蛋白偶联胶束及其制备方法 - Google Patents
一类具有抗急性淋巴细胞白血病活性的npm结合蛋白偶联胶束及其制备方法 Download PDFInfo
- Publication number
- CN111956608A CN111956608A CN202010302395.6A CN202010302395A CN111956608A CN 111956608 A CN111956608 A CN 111956608A CN 202010302395 A CN202010302395 A CN 202010302395A CN 111956608 A CN111956608 A CN 111956608A
- Authority
- CN
- China
- Prior art keywords
- peg
- pms
- binding protein
- npm
- ots
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000693 micelle Substances 0.000 title claims abstract description 45
- 102000014914 Carrier Proteins Human genes 0.000 title claims abstract description 32
- 108091008324 binding proteins Proteins 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 title claims abstract description 18
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 title claims abstract description 18
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 title claims abstract description 18
- 230000000694 effects Effects 0.000 title claims abstract description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 32
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 29
- 102100022678 Nucleophosmin Human genes 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 8
- 239000004626 polylactic acid Substances 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- 201000011510 cancer Diseases 0.000 claims abstract description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 78
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 32
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 22
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 10
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 230000002194 synthesizing effect Effects 0.000 claims description 7
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 238000000935 solvent evaporation Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims description 3
- OEOIWYCWCDBOPA-UHFFFAOYSA-N 6-methyl-heptanoic acid Chemical compound CC(C)CCCCC(O)=O OEOIWYCWCDBOPA-UHFFFAOYSA-N 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N p-toluenesulfonic acid Substances CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 238000007151 ring opening polymerisation reaction Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 230000000719 anti-leukaemic effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
- C08G63/688—Polyesters containing atoms other than carbon, hydrogen and oxygen containing sulfur
- C08G63/6882—Polyesters containing atoms other than carbon, hydrogen and oxygen containing sulfur derived from hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/78—Preparation processes
- C08G63/82—Preparation processes characterised by the catalyst used
- C08G63/823—Preparation processes characterised by the catalyst used for the preparation of polylactones or polylactides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/78—Preparation processes
- C08G63/82—Preparation processes characterised by the catalyst used
- C08G63/87—Non-metals or inter-compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开一类具有抗急性淋巴细胞白血病活性的NPM结合蛋白偶联胶束及其制备方法;是合成胶束(聚乙二醇对甲苯磺酸酯‑聚乳酸PLA‑PEG‑OTs);制备空白胶束(PMs);制备NPM1结合蛋白偶联胶束(PMs‑NPMBP)。该NPM结合蛋白偶联胶束的体外癌细胞抑制试验表明,对急性淋巴细胞白血病细胞具有一定的抑制活性,有望被开发为临床抗白血病药物,具有较好的应用前景。
Description
技术领域
本发明具体涉及一种具有抗急性淋巴细胞白血病活性的NPM结合蛋白偶联胶束的制备方法。
背景技术
纳米胶束,可增强药物的肿瘤靶向输送效率。NPM结合蛋白可特异靶向NPM1蛋白,而NPM1蛋白在难治复发ALL病人中高表达,并与耐药相关。将NPM结合蛋白与纳米胶束系统偶联,可望产生较好的靶向性和抗癌活性。
发明内容
本发明的目的在于提供一种具有抗急性淋巴细胞白血病活性的NPM结合蛋白偶联胶束及其制备方法,通过合成聚合胶束,丙酮溶剂蒸发法合成胶束,然后将NPM结合蛋白偶联至胶束。
为实现上述目的,本发明采用如下技术方案:
一类具有抗急性淋巴细胞白血病活性的NPM结合蛋白偶联胶束的制备方法,其特征在于:步骤如下:1)合成胶束(聚乙二醇对甲苯磺酸酯-聚乳酸 PLA-PEG-OTs);2)制备空白胶束(Polymeric micelles,PMs);3)制备NPM1结合蛋白偶联胶束(Polymeric micelles-Nucleophosmin-binding protein,PMs-NPMBP)。
所述的具有抗急性淋巴细胞白血病活性的NPM结合蛋白偶联胶束的制备方法,其特征在于:具体包括以下步骤:
1)胶束(聚乙二醇对甲苯磺酸酯-聚乳酸 PLA-PEG-OTs)的合成
首先合成一端含有对甲苯磺酸酯基团(-OTs)的PEG(HO-PEG-OTs)作为大分子引发剂,加入二氯甲烷(Dichloromethane,DCM),并加入三乙胺,使PEG 完全溶解;称取TsCl及DMAP,使用DCM 溶解后,缓慢滴加到含PEG的DCM 溶液中;采用开环聚合法合成PLA-PEG-OTs;
2)空白胶束(PMs)的制备
PMs采用丙酮溶剂蒸发法制备:取步骤1)制得的聚合物PLA-PEG-OTs 20 mg 于2 mL丙酮中搅拌溶解后,缓慢滴加入2 mL去离子水并搅拌混合均匀,35℃减压蒸馏除去大部分丙酮后,透析除去残留丙酮,得到透明澄清的PMs溶液;最后使用0.22 μm的滤膜无菌过滤备用;
3)NPM1结合蛋白偶联胶束(PMs-NPMBP)的制备
取步骤2)制得的浓度为10mg/mL的PMs水溶液,加入NPM结合蛋白,总体积为200 μL;混合均匀后避光放置于4℃条件下孵育12 h,得到NPM1结合蛋白PMs-NPMBP溶液。
所述的具有抗急性淋巴细胞白血病活性的NPM结合蛋白偶联胶束的制备方法,其特征在于:称取分子量为4000Da的聚乙二醇(PEG)4.6g,加入10 mL二氯甲烷(Dichloromethane,DCM),并加入0.3 g三乙胺于冰水浴4℃搅拌30 min,使PEG 完全溶解;称取4-甲苯磺酰氯(TsCl)0.2g 及4-二甲氨基吡啶(DMAP)12.2mg,使用30mL DCM溶解后,缓慢滴加到含PEG的DCM 溶液中,滴加完后恢复至室温继续搅拌反应24 h;减压蒸馏除去部分溶剂,过滤除去反应生成的盐,滤液于冰乙醚沉淀两次,过滤收集产物,室温真空干燥即得白色粉末状的HO-PEG4000-OTs;然后称取HO-PEG-OTs 1g,D,L-丙交酯适量,异辛酸亚锡(Sn(Oct)2)(质量为丙交酯的0.5 wt%)溶于无水甲苯中,于130℃搅拌反应24 h反应结束以后,将反应产物溶于无水DCM中,于冰乙醚中沉淀两次,过滤收集产物,真空干燥即得产物;通过调整加入丙交酯的量以获得不同亲疏水链比的PLA-PEG-OTs。
本发明所述的方法制得的具有抗急性淋巴细胞白血病活性的NPM结合蛋白偶联胶束在制备抑制活性或/和治疗癌细胞药物中的应用。
上述的癌细胞包括白血病Nalm6。
为实现上述目的,本发明采用如下具体技术方案:
合成胶束(聚乙二醇对甲苯磺酸酯-聚乳酸 PLA-PEG-OTs);制备空白胶束(PMs);制备NPM1结合蛋白偶联胶束(PMs-NPMBP)。
其具体包括以下步骤:
1)胶束(聚乙二醇对甲苯磺酸酯-聚乳酸 PLA-PEG-OTs)的合成
首先合成一端含有对甲苯磺酸酯基团(-OTs)的PEG(HO-PEG-OTs)作为大分子引发剂,加入二氯甲烷(Dichloromethane,DCM),并加入三乙胺,使PEG 完全溶解。称取TsCl及DMAP,使用DCM 溶解后,缓慢滴加到含PEG的DCM 溶液中。采用开环聚合法合成PLA-PEG-OTs。
2)空白胶束(PMs)的制备
PMs采用丙酮溶剂蒸发法制备。取聚合物PLA-PEG-OTs 20 mg 于2 mL丙酮中搅拌溶解后,缓慢滴加入2 mL去离子水并搅拌混合均匀,35℃减压蒸馏除去大部分丙酮后,透析除去残留丙酮,得到透明澄清的PMs溶液。最后使用0.22 μm的滤膜无菌过滤备用。
3)NPM1结合蛋白偶联胶束(PMs-NPMBP)的制备
取上述PMs水溶液适量(10 mg/mL),加入NPM结合蛋白,总体积为200 μL。混合均匀后避光放置于4℃条件下孵育12 h,得到NPM1结合蛋白PMs-NPMBP溶液。
本发明的显著优点在于:本发明所制得的具有抗急性淋巴细胞白血病活性的NPM结合蛋白偶联胶束合成步骤简单,结构明确,对急性淋巴细胞白血病细胞具有一定的抑制作用。该化合物含有NPM结合蛋白,可靶向抑制癌细胞NPM蛋白的表达,使得本专利合成的化合物具有一定的抗癌活性和靶向性,具有较高的开发为抗白血病药物的应用前景。
附图说明
图1为本发明的不同处理组NPM蛋白表达的差异图,图中:*p<0.05。
具体实施方式
为了使本发明所述的内容更加便于理解,下面结合具体实施方式对本发明所述的技术方案做进一步的说明,但是本发明不仅限于此。
实施例1:胶束(聚乙二醇对甲苯磺酸酯-聚乳酸 PLA-PEG-OTs)的合成
称取分子量为4000Da的聚乙二醇(PEG)4.6 g,加入10 mL二氯甲烷(Dichloromethane,DCM),并加入0.3 g三乙胺于冰水浴4℃搅拌30 min,使PEG 完全溶解。称取4-甲苯磺酰氯(TsCl)0.2 g 及4-二甲氨基吡啶 (DMAP) 12.2 mg,使用30 mL DCM 溶解后,缓慢滴加到含PEG的DCM 溶液中,滴加完后恢复至室温继续搅拌反应24 h。减压蒸馏除去部分溶剂,过滤除去反应生成的盐,滤液于冰乙醚沉淀两次,过滤收集产物,室温真空干燥即得白色粉末状的HO-PEG4000-OTs。然后称取HO-PEG-OTs 1 g,D,L-丙交酯适量,异辛酸亚锡(Sn(Oct)2)(质量为丙交酯的0.5 wt %)溶于无水甲苯中,于130℃搅拌反应24 h反应结束以后,将反应产物溶于无水DCM中,于冰乙醚中沉淀两次,过滤收集产物,真空干燥即得产物。通过调整加入丙交酯的量以获得不同亲疏水链比的PLA-PEG-OTs。
实施例2:空白胶束(PMs)的制备
PMs采用丙酮溶剂蒸发法制备[Int. J. Pharm. 2007, 329, 158–165]。取实施例1制得的聚合物PLA-PEG-OTs 20 mg 于2 mL丙酮中搅拌溶解后,缓慢滴加入2 mL去离子水并搅拌混合均匀,35℃减压蒸馏除去大部分丙酮后,透析除去残留丙酮,得到透明澄清的PMs溶液。最后使用0.22 μm的滤膜无菌过滤备用。
实施例3:NPM结合蛋白偶联胶束(PMs-NPMBP)的制备
应用原核蛋白表达方法,合成纯化的NPM1蛋白,从Scatin骨架蛋白库中筛选,获得非抗体类的Scatin结合蛋白,即NPM结合蛋白。取实施例2制得的PMs水溶液适量(10 mg/mL),分别加入20 μL、40 μL、80 μL NPM结合蛋白(1.5 mg/mL),总体积为200 μL。混合均匀后避光放置于4℃条件下孵育12 h,得到NPM结合蛋白浓度分别为0.15 mg/mL、0.3 mg/mL、0.6 mg/mL的PMs-NPMBP溶液。
实施例4:PMs-NPMBP对白血病细胞增殖抑制实验
将NPM结合蛋白偶联胶束(PMs-NPMBP)作为受试药物,用培养基将药物稀释。将人急性淋巴细胞白血病细胞株Nalm-6的密度调整为3×105个/mL,接种于96孔板,每孔100μL,置37℃、5% CO2培养箱中培养24 h;移去旧的培养基,加入受试药物(浓度分别从0.156μM -10μM),每孔100μL,另设空白对照组,设3个复孔。药物作用48h后,加入MTT溶液20μL,继续孵育4h,终止培养;小心吸弃96孔板孔内上清液,每孔加入100μL DSMO,振荡10min,在酶标仪上于490nm和630nm波长处测定各孔光吸收值(OD值)。结果如表1所示。
表1 不同浓度PMs-NPMBP (μM)对急性淋巴细胞白血病细胞Nalm-6的
增殖抑制率(%)
细胞株 | 0.156 | 0.312 | 0.625 | 1.25 | 2.5 | 5 | 10 |
Nalm-6 | 6.4 | 12.6 | 15 | 19.1 | 26.1 | 29.1 | 30.6 |
结果表明,PMs-NPMBP在一定浓度范围内对白血病细胞呈浓度依赖性抗白血病活性。
实施例5:PMs-NPMBP靶向抑制NPM的蛋白印迹实验
收集对数生长期的Nalm-6细胞,调整细胞接种浓度为2×105/ml,24h后收集阴性对照组、5μM PMs-NPMBP处理组,收集蛋白。如图1所示,经蛋白免疫印迹实验,Nalm-6细胞PMs-NPMBP处理组的NPM蛋白表达下调,表达量为阴性对照组的0.887 ± 0.014,差异具有显著性。
总体来看,NPM结合蛋白偶联胶束(PMs-NPMBP)具有一定的抗癌活性,并对NPM蛋白具有靶向性,因而有较高的开发为抗癌药物的市场潜力。以上所述仅为本发明的较佳实施例,凡依本发明申请专利范围所做的均等变化与修饰,皆应属本发明的涵盖范围。
Claims (5)
1.一类具有抗急性淋巴细胞白血病活性的NPM结合蛋白偶联胶束的制备方法,其特征在于:步骤如下:1)合成胶束(聚乙二醇对甲苯磺酸酯-聚乳酸 PLA-PEG-OTs);2)制备空白胶束(Polymeric micelles,PMs);3)制备NPM1结合蛋白偶联胶束(Polymeric micelles-Nucleophosmin-binding protein,PMs-NPMBP)。
2.根据权利要求1所述的具有抗急性淋巴细胞白血病活性的NPM结合蛋白偶联胶束的制备方法,其特征在于:具体包括以下步骤:
1)胶束(聚乙二醇对甲苯磺酸酯-聚乳酸 PLA-PEG-OTs)的合成
首先合成一端含有对甲苯磺酸酯基团(-OTs)的PEG(HO-PEG-OTs)作为大分子引发剂,加入二氯甲烷(Dichloromethane,DCM),并加入三乙胺,使PEG 完全溶解;称取TsCl及DMAP,使用DCM 溶解后,缓慢滴加到含PEG的DCM 溶液中;采用开环聚合法合成PLA-PEG-OTs;
2)空白胶束(PMs)的制备
PMs采用丙酮溶剂蒸发法制备:取步骤1)制得的聚合物PLA-PEG-OTs 20 mg 于2 mL丙酮中搅拌溶解后,缓慢滴加入2 mL去离子水并搅拌混合均匀,35℃减压蒸馏除去大部分丙酮后,透析除去残留丙酮,得到透明澄清的PMs溶液;最后使用0.22 μm的滤膜无菌过滤备用;
3)NPM1结合蛋白偶联胶束(PMs-NPMBP)的制备
取步骤2)制得的浓度为10mg/mL的PMs水溶液,加入NPM结合蛋白,总体积为200 μL;混合均匀后避光放置于4℃条件下孵育12 h,得到NPM1结合蛋白PMs-NPMBP溶液。
3.根据权利要求2所述的具有抗急性淋巴细胞白血病活性的NPM结合蛋白偶联胶束的制备方法,其特征在于:称取分子量为4000Da的聚乙二醇(PEG)4.6g,加入10 mL二氯甲烷(Dichloromethane,DCM),并加入0.3 g三乙胺于冰水浴4℃搅拌30 min,使PEG 完全溶解;称取4-甲苯磺酰氯(TsCl)0.2g 及4-二甲氨基吡啶(DMAP)12.2mg,使用30mL DCM溶解后,缓慢滴加到含PEG的DCM 溶液中,滴加完后恢复至室温继续搅拌反应24 h;减压蒸馏除去部分溶剂,过滤除去反应生成的盐,滤液于冰乙醚沉淀两次,过滤收集产物,室温真空干燥即得白色粉末状的HO-PEG4000-OTs;然后称取HO-PEG-OTs 1g,D,L-丙交酯适量,异辛酸亚锡(Sn(Oct)2)(质量为丙交酯的0.5 wt%)溶于无水甲苯中,于130℃搅拌反应24 h反应结束以后,将反应产物溶于无水DCM中,于冰乙醚中沉淀两次,过滤收集产物,真空干燥即得产物;通过调整加入丙交酯的量以获得不同亲疏水链比的PLA-PEG-OTs。
4.一种如权利要求1-3任一所述的方法制得的具有抗急性淋巴细胞白血病活性的NPM结合蛋白偶联胶束在制备抑制活性或/和治疗癌细胞药物中的应用。
5.根据权利要求4所述的应用,其特征在于:所述的癌细胞包括白血病Nalm6。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010302395.6A CN111956608A (zh) | 2020-04-17 | 2020-04-17 | 一类具有抗急性淋巴细胞白血病活性的npm结合蛋白偶联胶束及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010302395.6A CN111956608A (zh) | 2020-04-17 | 2020-04-17 | 一类具有抗急性淋巴细胞白血病活性的npm结合蛋白偶联胶束及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111956608A true CN111956608A (zh) | 2020-11-20 |
Family
ID=73357923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010302395.6A Pending CN111956608A (zh) | 2020-04-17 | 2020-04-17 | 一类具有抗急性淋巴细胞白血病活性的npm结合蛋白偶联胶束及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111956608A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103520731A (zh) * | 2013-09-27 | 2014-01-22 | 华南理工大学 | 一种包裹疏水性抗癌药物的叶酸-聚乙二醇-聚乳酸嵌段共聚物胶束及其制备方法 |
US20190290680A1 (en) * | 2016-07-15 | 2019-09-26 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
-
2020
- 2020-04-17 CN CN202010302395.6A patent/CN111956608A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103520731A (zh) * | 2013-09-27 | 2014-01-22 | 华南理工大学 | 一种包裹疏水性抗癌药物的叶酸-聚乙二醇-聚乳酸嵌段共聚物胶束及其制备方法 |
US20190290680A1 (en) * | 2016-07-15 | 2019-09-26 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
Non-Patent Citations (4)
Title |
---|
JIANDA HU等: "Nucleophosmin/B23(NPM) As a New Prognostic Predictor in Acute Lymphoblastic Leukemia", 《BLOOD》 * |
周誉等: "靶向急性髓系白血病特定基因亚型的治疗研究进展", 《中国现代应用药学》 * |
姜坤等: "急性白血病相关基因检测的临床意义", 《现代医学》 * |
郑毅等: "抗人CD40单克隆抗体偶联纳米胶束药物载体系统的构建及其生物学特性", 《中国肿瘤生物治疗杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6624603B2 (ja) | 抗菌性のカチオン性ポリカーボネート | |
JP6391671B2 (ja) | 抗菌性のカチオン性ポリカーボネート | |
CN102352042A (zh) | 侧链功能化修饰的生物可降解型两亲性聚酯 | |
CN102260356A (zh) | 一种用作基因载体的壳聚糖衍生物及其制备方法和用途 | |
EP3613792B1 (en) | Multi-arm targeted anti-cancer conjugate | |
CN107001603A (zh) | 用于医疗应用的水溶性聚碳酸酯 | |
CN111973748A (zh) | Enpp1抑制剂与抗癌药物联合用药在制备抗肿瘤药物中的应用 | |
US9796728B2 (en) | Cyclic carbonate monomer containing double-sulfur five-membered ring functional group, and preparation method thereof | |
US20190060463A1 (en) | Bridged polyethylene glycol-aliphatic polyester block copolymer, preparation method for same, intermediate of same, and uses thereof | |
CN106995528A (zh) | 一种聚乙二醇单甲醚-聚乳酸嵌段共聚物的精制方法 | |
CN111956608A (zh) | 一类具有抗急性淋巴细胞白血病活性的npm结合蛋白偶联胶束及其制备方法 | |
CN103288788A (zh) | 一种δ-戊内酯类化合物、制备方法和应用 | |
CN111686261B (zh) | 一类具有抗急性淋巴细胞白血病活性的npm1结合蛋白偶联阿霉素胶束及其制备方法 | |
CN102336904B (zh) | 一种喜树碱及其衍生物的多价peg修饰物及其用途 | |
CN102532533B (zh) | 一种聚(天冬氨酸-co-乳酸)-磷脂酰乙醇胺接枝聚合物及其制备方法和应用 | |
CN111363170A (zh) | 一种羟乙基纤维素-海藻酸钠水凝胶的制备和应用 | |
CN101066456A (zh) | 药物植入缓释载体材料及其制备方法 | |
CN115105526B (zh) | 改性pamam聚合物在制备抗肿瘤药物中的应用 | |
CN112961337B (zh) | 甘氨双唑钠聚乙二醇聚天冬氨酸聚合物及其制备方法 | |
CN112545989B (zh) | 一种甘氨双唑钠聚乙二醇聚天冬氨酸聚合物的应用 | |
CN108727582A (zh) | 靶向抗癌偶联物 | |
CN108129652B (zh) | 一种聚乙二醇赖氨酸马来酰亚胺硫鸟嘌呤结合物 | |
CN111329857A (zh) | 一种氟苯甲酰胺衍生物注射液及其抗乳腺癌应用 | |
CN116375789A (zh) | 一种抗肿瘤化合物、其制备方法、药物组合物及应用 | |
JPH11269065A (ja) | 癌細胞のアポトーシス耐性の克服剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201120 |
|
RJ01 | Rejection of invention patent application after publication |